Dengue vaccines: dawning at last?

The Lancet
Oct 11, 2014 Volume 384 Number 9951 p1321 – 1400 e49 – 51
http://www.thelancet.com/journals/lancet/issue/current

Dengue vaccines: dawning at last?
Annelies Wilder-Smith
Preview |
The need for a dengue vaccine is more pressing than ever. Dengue—a mosquito-borne viral infection caused by any of the four dengue virus serotypes—is regarded as the most important arboviral disease globally, because more than 50% of the world’s population live in regions at risk of the disease, and evidence points towards further geographical and numerical expansion.1 The results of Maria Capeding and colleagues’ multicentre phase 3, randomised, observer-masked, placebo-controlled efficacy trial2 for a recombinant, chimeric, live attenuated tetravalent dengue vaccine (CYD-TDV), in The Lancet, have been awaited with great anticipation paired with some trepidation, on the basis of the disappointing results from a previous single-centre trial with the same vaccine in Thailand.